Zilebesiran is an investigational RNAi therapeutic that is currently being studied in clinical trials

Click below to learn more about zilebesiran through educational and scientific materials.

MOA of zilebesiran depicting siRNA loading into RISC

About Zilebesiran

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Publication Date

July 2023

Journal

The New England Journal of Medicine

Authors

Akshay Desai, David Webb, Jorg Taubel, et al

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

Publication Date

February 2024

Journal

The Journal of the American Medical Association

Authors

George L Bakris, Manish Saxena, Anil Gupta, et al

For more information about data regarding zilebesiran, please visit our Congresses & Publications page.

Currently Enrolling Trials

Phase/Status	Trial Name	Description
Phase 2 ENROLLING	Image	Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) Adults aged ≥18 years with a confirmed diagnosis of hypertension may be eligible* ClinicalTrials.gov: NCT06272487 For more information about KARDIA-3: Call study information center at 1-877-256-9526 Email Medical Information at medinfo@alnylam.com

Phase/Status

Trial Name

Description

Phase 2
ENROLLING

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Adults aged ≥18 years with a confirmed diagnosis of hypertension may be eligible*

ClinicalTrials.gov: NCT06272487

For more information about KARDIA-3:

Call study information center at 1-877-256-9526
Email Medical Information at medinfo@alnylam.com

Phase/Status
Phase 2 ENROLLING

Trial Name
Image

Trial Name

Description
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) Adults aged ≥18 years with a confirmed diagnosis of hypertension may be eligible* ClinicalTrials.gov: NCT06272487 For more information about KARDIA-3: Call study information center at 1-877-256-9526 Email Medical Information at medinfo@alnylam.com

Description

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Adults aged ≥18 years with a confirmed diagnosis of hypertension may be eligible*

ClinicalTrials.gov: NCT06272487

For more information about KARDIA-3:

Call study information center at 1-877-256-9526
Email Medical Information at medinfo@alnylam.com

*Additional eligibility criteria apply.